FDA-approved for treatment of skin and skin-structure infections and intraabdominal infections.
Management of intra-abdominal infections in patients with contraindications to both betalactams and fluoroquinolones.
Management of infections due to multidrug resistant Gram-negative organisms including Acinetobacter on a case by case basis.
Salvage therapy for MRSA or VRE infections on a case by case basis.
Bacteremia and endocarditis.
Tigecycline should not be used to treat pneumonia as unacceptably high failure rates have been reported (see black box warning).
Reserved for highly resistant infections or when significant allergies restrict other options and when there is documented susceptibility
Associated with more treatment failures than alternatives and excess mortality - Black Box Warning
Avoid or use with caution in patients with tetracycline reactions
GI side effects very prominent with significant nausea and vomiting
Tetracycline related adverse events: photosensitivity, acute pancreatitis
Rash, abnormal liver enzymes
Oral contraceptives less effective
Requires Infectious Disease consultation
Documented safety concerns in bacteremia especially. Avoid in bloodstream infection
Antimicrobial class: Tetracycline derivative
Pregnancy category: D
Average serum half life: 42 hours
Biliary penetration: Therapeutic
Lung penetration: Therapeutic